Category: United States
-
Incyte acquires bleeding-disorder biotech Vega Therapeutics as Jakafi patent cliff looms
Incyte will pay $1.25 billion upfront for Vega Therapeutics, with up to $750 million more in sales milestones. The $2.4 billion-a-year drug loses U.S. exclusivity in December 2028 after a pediatric extension.
-
NPEs seeking U.S. patent injunctions won’t benefit from Judge Gilstrap’s clearly erroneous finding of irreparable harm in Collision v. Samsung
Some defense-focused patent litigators warn against the potential fallout from Judge Gilstrap’s Collision v. Samsung decision while enforcement-oriented lawyers see opportunities for NPEs. But the part that gets everyone excited is clear legal error.
-
Samsung argues non-infringement or breach of (F)RAND obligations in latest Netlist bout
The Korean company’s District of Delaware complaint follows its targeting in a Netlist infringement action filed on the same day that the patent-in-suit was issued.
-
Supreme Court holds generics maker Hikma not liable for induced infringement: inducement must be “clear” and “affirmative”
A unanimous Supreme Court says the Federal Circuit has been on the wrong track lately by loosening the standard for induced infringement.
-
USPTO launches expedited examination pilot aimed at incentivizing small business, research sector participation in standard-setting
While laudable, it isn’t clear that the SPARK Pilot Program can significantly move the needle.
-
Micron files declaratory judgment action on same day as patent grant in expansion of chipmakers’ fight with Netlist
The dispute over JEDEC-compliant memory technologies continues with a newly issued patent in the mix.
-
President Trump nominates three new ITC Commissioners, including IP expert
The ITC has only had three of its six Commissioners since February 2025, with those remaining all approaching the end of their terms.
-
Moderna appeals to save $1.3 billion patent dispute payout, asserts U.S. government-contractor immunity
Moderna has alleged that a district courtâs conclusions in a case against Arbutus are âdeeply flawedâ and that the U.S. Congress created Section 1498 specifically to shield government contractors from liability for government-authorized patent use in fulfilling a government procurement contract.
-
Multiple amicus briefs filed after Google’s Supreme Court petition questioning USPTO’s “settled expectations” approach
Google argues the agency “has exceeded its statutory authority” in refusing to review patents in force for more than six years.
-
An interview with IP monetization âgodfatherâ Marshall Phelps
âIf you let them, patents can permit people to do so many things, and they can pay you for the privilege,â Marshall Phelps recently told ip fray in an exclusive interview.